Peripheral blood stem cells (PBsCs) mobilized with highdose chemotherapy and hematopoietic growth factors are now widely used t o support myeloablative therapy of multiple myeloma and effect complete remissions in up t o 50% of patients with apparent extension of event-free and overall survival. Because tumor cells are present not only in bone marrow, but also in virtually all PBSC harvests, it is conceivable that autografted myeloma cells contribute t o relapse after autotransplants. In this study, the kinetics of mobilization of normal hematopoietic stem cells were compared with those of myeloma cells present in PBSC harvests of 12 patients after high-dose cyclophosphamide and granulocyte-macrophage colony-stimulating factor administration. CD34+ and CD34+Lin-Thy+ stem cell contents were measured by multiparameter flow cytometry, and myeloma cells were quantitated by immunostaining for the relevant Ig light chain and by a quantitative polymerase chain reaction for UTOLOGOUS TRANSPLANTATION is now frequently used in the treatment of patients with multiple myeloma (MM)."4 Complete remissions (CRs) are observed in up to 50% of patients with newly diagnosed MM, but, unfortunately, relapses remain a pr~blem.',~" Compared with standard autologous bone marrow (BM) transplants, peripheral blood stem cells (PBSCs) procured after the administration of high-dose cyclophosphamide and/or hematopoietic growth factors significantly reduce the duration of BM aplasia and hence treatment-related morbidity and mortality.'"' Because MM is a disease considered to be restricted to the BM, the concentration of myeloma cells in PBSCs was felt to be negligible. However, we and others have documented tumor cells in PBSC harvests with a frequency of 0.01% to greater than This observation prompted the exploration of hemopoietic stem cell selection as a means of reducing tumor cell ~ontamination.'~ We have focused on a CD34+ subcompartment that expresses Thy+ and Lin-(CD34', Thy+, Lin-) and is composed of cells capable of unlimited self-renewal and multilineage differentiation.14"' This fraction contains less than 0.001% myeloma cells, based on polymerase chain reaction (PCR) amplification of the CDRIII sequence.13
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MATERIALS AND METHODS
Mobilization
Quantitation of CD34'Lin-Thy' stem cells. Stem cells were detected by staining samples from apheresed blood (1 0' cells) for CD34 using anti CD34-PE (HPCA-2; BD) and for Thy (CD,90) using biotin-labeled GM 201 (SyStemix, Palo Alto, CA), followed by RED 670-streptavidin (Systemix). Lin' cells were stained with FITCconjugated antibodies to CD14, CDIS, CD2, CD16, CD19, and antiglycophorin (all from BD). Isotypic controls corresponding to the antibody isotypes and the proper fluorochrome were used to determine the background staining. IgG l-biotin and avidin-RED 670 were used as a control for the Thy antibody. Propidium iodide was added to all tubes to exclude dead cells. Tubes were run on a FACSCAN BOW cytometer (BD). Six parameters (FS, SS, PI, FITC, PE, and Red 670) were examined in listmode using the ListView software (Phoenix Flow Systems, San Diego, CA). The cells were sequentially gated from viable nucleated cells to the lymphoblastoid region and then to each of the two color combinations, ie. CD34 versus Lin and CD34 versus Thy. Each fluorochrome was color gated. Fifty thousand cells were analyzed.
Sruiningfor myeloma cells. Staining of myeloma cells was performed on cytospins
(50,000 cells from apheresis samples) after ethanol fixation (30 minutes at 4°C). Slides were stained for both K and X light chains of human Ig (rabbit antibody-Rhodamine conjugate; Dako, Carpinteria, CA). Plasma cells were identified by positive staining for the pertinent light chain and by their lymphoid/ plasmacytoid morphology. Positive staining for the irrelevant light chain was always less than 10% of the relevant light chain. At least S00 cells were scored.
Staining of immuture myeloma cells und determination of plusma cell labeling index (PCLI).
Several methods for determination of PCLI were tested using different anti BrdU antibodies and different cell denaturation protocols as described previously.2' The best results were obtained using the procedure described by Lokhorst et al." Briefly, samples from apheresed blood (10' cells) were allowed to incorporate bromodeoxyuridine ( I 0 pmol/L BrdU for 1 hour at 37°C). Subsequently, aliquots of 50,000 cells were cytospun, fixed with ethanol, air-dried, and treated with 2 N HCI (30 minutes at room temperature) to denature DNA. After neutralization in phosphatebuffered saline (PBS), slides were stained for K and A light chains as described above and for BrdU with anti-BrdU antibodies (mouse monoclonal; Dako), followed by antimouse-FITC (Jackson Immunochemicals, West Grove, PA). Double-stained cells were counted as cycling p k m d cells. Cycling plasma cells were identified by positive staining for the relevant light chain (red), by positive staining for BrdU (green), and by their lymphoidlplasmacytoid appearance. Positive staining for the irrelevant light chain was less than 10% of the relevant light chain. At least 500 plasma cells were scored. Mouse lgGI was used as a control for background staining for the BrdU antibody. This procedure was used successfully in our laboratory for more than 1 year to monitor more than 400 patients with significant correlation between disease activity and PCLI (Gazitt, manuscript in preparation).
Immature plasma cells were detected by cytoplasmic staining for K/A light chain (rhodamine-conjugated antibodies), as described above, and for CD19' using FITC-anti-CD19 antibody (mouse, monoclonal; BD). Most CDIY' cells were small lymphocytoid, with predominant membrane staining for CD19. In 2 patients. CD19' cells had the appearance of plasmacytoid cells with weak staining for cytoplasmic CD19 antigen and positive staining for the relevant light chain. Positive staining of CD19' cells with the irrelevant light chain was always less than 1070 of the relevant light chain. At least S00 plasma cells were scored. Mouse FITC-IgGI was used as isotypic control for background staining for the CD19 antibody.
RESULTS
The time course of stem cell mobilization for 4 representative patients is depicted in Fig I . Maximum proportions of CD34' and CD34'Lin-Thy' were observed on days 1 to 3, ranging from 1.8% to 22.2% and 0.48% to 8.2%. respectively. Figure 2 portrays the cumulative amount of CD34' stem cells in the 12 MM patients studied. Sufficient quantities of CD34+ cells per kilogram for two autotransplants (>4 X 10' ) were obtained after two collections in 9 of the 12 patients. Eight patients mobilized greater than 10 X loh/ kg of CD34' cells within the first 3 days of collection. Three patients did not mobilize well.
The proportions of myeloma cells in PBSC harvests of 4 patients, including the percentages of light chain restricted B cells (PLC), their labeling index (PCLI), and the proportion of immature myeloma cells (CD19') are depicted in Fig  3. In all 4 patients, mobilization of myeloma cells peaked on days S and 6, with PCLI values ranging between 3.1 % and 7.5% on these days. Maximum concentrations of light chain-restricted CD19' cells (presumed to represent preplasmacytic myeloma cells) usually coincided with peak values of PCLI. The cumulative amount of myeloma cells in the I2 myeloma patients is depicted in Fig 4. Ten patients mobilized greater than S X 107/kg and 6 greater than 1 X lORkg myeloma cells during the 6 days of apheresis. One patient did not mobilize significant amounts of myeloma cells. In the other 11 patients, greater than 75% of myeloma cells were collected during the last 2 days of apheresis.
Figure S summarizes the proportions of CD34'. CD34'Lin Thy*, and myeloma cells during the consecutive days of PBSC apheresis. Median percentages of maximum CD34' and CD34'Lin-Thy' cells were 5.5% (range, 0.2% to 22.2%) and 2.7% (range. 0.1% to 8.2%), respectively. Both cell populations were largest on days 1 to 3, with a subsequent significant decline reaching a minimum by day 6 ( P < .001). In contrast, only 2 of 12 patients had ~2 . 5 % myeloma cells by immunocytochemistry in their PBSC collections on days 1 and 2, compared with 1 I of 12 patients by day 6. A median of 4.4% myeloma cells (range, 1.6% to 10.9%) were cycling, most frequently on days 4 to 6 of PBSC collection. Similarly, CD19' light chain-restricted cells peaked on day 6, with a median of 5.1% (range, 0% to 16%; results not shown). The least overlap between hematopoietic progenitor and myeloma cell mobilization was observed on days I and 2.
PCR-based quantitation of minimal residual disease is more sensitive (2 to 3 logs) than immunofluorescence-based quantitation of tumor cells. Therefore, quantitation of myeloma cells in PBSC collections was also performed by PCR amplification of the clone-specific CDRIII sequence. 
DISCUSSION
Mobilization of PBSCs with high-dose chemotherapy alone or in combination with hematopoietic growth factors results in a 10-to 100-fold increase in the number of circulating hematopoietic progenitor ~e l l s~~. '~ and effects prompt, complete and durable engraftment after myeloablative treatment."" Probably not unexpectedly, this approach also leads to mobilization of tumor ~e l l s , ' '~~~ including myeloma Myeloma cells are present in virtually all mobilized PBSC harvests with a frequency of 0.01% to greater than 10%.l3 Depletion of myeloma cells can be achieved by positive selection for CD34+ cells" or, more completely, by selection for CD34+Thy+Lin-stem cells. '3 This is the first detailed study assessing, simultaneously, the kinetics of mobilization of both hematopoietic progenitor cells and myeloma cells, including their proliferative capacity and the immature myeloma cell phenotype. The highest proportions of progenitor cells (CD34' and CD34+ThytLin-cells) were observed during the first 2 days of apheresis, when the total white blood cell (WBC) count was still low (0.5 to 2 X 109/L). More than 4 X 106/kg CD34+ cells, sufficient for two auto transplant^,^ were collected during the first 2 days in 9 of the 12 patients. Two of the three patients high progenitor cell content and minimal myeloma cell contamination exists during the first few days after W C and platelet counts start to recover.
Moreover, during the last days of apheresis, a significant proportion of myeloma cells was cycling and exhibited a more immature phenotype (CD19+). Both immunocytochemical and PCR-based methodologies detected comparable amounts of myeloma cells in the daily collections (R values of 0.93 to 0.97). The more sensitive PCR-based assay showed a daily increase in concentration of myeloma cells by 1 log in several patients.
Whether mobilization of myeloma cells is the result of cyclophosphamide treatment or the administration of hematopoietic growth factor remains unknown. We are currently conducting a study comparing the yield of CD34+ cells and degree of myeloma cell contamination in MM patients mobilized with either G-CSF or G-CSF plus cyclophosphamide. -. .
.
.. Fig 3A) concurs with a decrease in CD34'Lin-Thy' cells from a median of 2.7% on day 1 t o 0.29% on day 6 (Fig 38) . Median percentages of myeloma cells were low on days l through 3 10.3546, 0.650/0, and 1.846, respectively) and increased markedly on days 4 through 6 (4.2%. 5.7%. and 11.2%; Fig 3C) . growth factors in umbilical cord blood" and their effect on the expression of the adhesion molecules, ELAM-l and ICAM-I.37 Umbilical cord blood induces rapid hematopoietic engraftment after myeloablative treatment. Interestingly, CD34' cells express increased levels of L-selectin after PBSC mobilization strategies, which correlated with the speed of hemopoietic engraftment.3x
While depletion methods for myeloma cells from PBSCs are currently being we recommend that, in the absence of such methods, large volume exchanges early after leukocyte and platelet recovery are perf~rmed.'"~~' Our conclusions are supported by the absence of breast cancer cells, as measured by sensitive immunocytochemistry and clonogenic assays, in single day large volume PBSC collections.."
